Affimed NV $ 5.13 -0.47 (-8.39%)
Warning! GuruFocus has detected 4 Severe warning signs with AFMD. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for AFMD (Affimed NV) from 2014 to Mar 04 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Affimed NV stock (AFMD) PE ratio as of Mar 04 2021 is 0. More Details
Affimed NV PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Affimed NV PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:XCUR NAS:XOMA NAS:MNOV AMEX:PFNX NAS:KLDO NAS:CMRX NAS:AVXL NAS:GRTS NAS:FPRX NAS:NYMX OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address Im Neuenheimer Feld 582, Technologiepark, Heidelberg, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.